ASCLS eNewsBytes

• Tiny Parasite, Big Problem: Managing Cyclosporiasis in Pediatric Patients August 25, 2026
  Cyclosporiasis is an intestinal infection caused by the parasite Cyclospora cayetanensis, spread through contaminated food or water. The oocysts take 1 to 2 weeks to become infectious, minimizing person-to-person transmission and complicating outbreak tracking. Symptoms include gastrointestinal distress and watery diarrhea, with aggressive rehydration being critical. Typically self-limiting, antibiotics such as sulfamethoxazole-trimethoprim may be required […]
• Ultrasound Contrast Delivery System Receives FDA Clearance August 25, 2026
  VueJect, an ultrasound contrast delivery system designed for cardiology imaging, has obtained 510(k) clearance from the U.S. FDA and authorization from Health Canada.
• FDA-Approved Mucinex 12HR Cold & Fever Multi-Symptom Brings 12-Hour OTC Relief for Cough, Fever, Pain August 25, 2026
  The FDA has approved Mucinex 12HR Cold & Fever Multi-Symptom, an over-the-counter medication designed to offer up to 12 hours of relief from cough, chest congestion, fever, headache and minor body pain related to the common cold.
• Growth Hormone Therapy Improves Height After Childhood Stem Cell Transplants August 25, 2026
  Hematopoietic stem cell transplantation is a curative treatment for life-threatening cancers and nonmalignant disorders, particularly in children. Although historically risky, medical advances have improved long-term survival rates. However, these survivors often experience late effects, notably growth impairment and short stature.
• Drug Turns Off 'Master Switch' in Aggressive Breast Cancer August 25, 2026
  A drug targeting a key regulator in triple-negative breast cancer shows promise by inhibiting tumor growth and cancer stem cell viability in laboratory models. This aggressive subtype affects primarily women under 40 and represents 15-20% of breast cancer cases, complicating treatment due to the lack of receptors for estrogen, progesterone, and HER2.